MeVis Medical Solutions AG (DE:M3V)
XETRA:M3V
Want to see DE:M3V full AI Analyst Report?
Top Page
MeVis Medical Solutions
(XETRA:M3V)
Select Model
Select Model
Rating:72Outperform
Price Target:
€27.00
▲(9.76% Upside)
Action:Reiterated
Date:02/02/26
The score is driven primarily by strong financial quality (notably a debt-free balance sheet and historically high margins) and supportive valuation (low P/E and solid dividend yield). These positives are partially offset by weakening revenue/profit trends and bearish technicals (price below key moving averages despite oversold RSI).
Positive Factors
Debt-free balance sheet
A zero-debt, equity-stable balance sheet materially lowers financial risk and preserves strategic optionality. Over months this supports consistent R&D and product engineering investment, resilience through contract seasonality, and the ability to fund opportunistic M&A or partnerships without refinancing strain.
Negative Factors
Three-year revenue decline
A persistent multi-year top-line contraction signals structural challenges in demand, customer retention, or competitive positioning. Continued revenue declines can erode operating leverage, limit reinvestment capacity for product roadmap execution, and ultimately pressure long-term revenue growth prospects and market share.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-free balance sheet
A zero-debt, equity-stable balance sheet materially lowers financial risk and preserves strategic optionality. Over months this supports consistent R&D and product engineering investment, resilience through contract seasonality, and the ability to fund opportunistic M&A or partnerships without refinancing strain.
Read all positive factors
MeVis Medical Solutions (M3V) vs. iShares MSCI Germany ETF (EWG)
Market Cap
€42.95M
Dividend Yield3.86%
Average Volume (3M)99.00
Price to Earnings (P/E)―
Beta (1Y)0.20
Revenue Growth-5.36%
EPS Growth-30.58%
CountryDE
Employees100
SectorGeneral
Sector StrengthN/A
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)2.36
Shares Outstanding1,820,000
10 Day Avg. Volume191
30 Day Avg. Volume99
Financial Highlights & Ratios
PEG Ratio-0.46
Price to Book (P/B)2.53
Price to Sales (P/S)2.81
P/FCF Ratio12.07
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
MeVis Medical Solutions Business Overview & Revenue Model
Company Description
MeVis Medical Solutions AG develops, markets, and sells software for analyzing and evaluating image data to equipment manufacturers of medical devices, providers of medical IT platforms, and clinical end customers in the United States and Europe. ...
How the Company Makes Money
MeVis Medical Solutions generates revenue through the sale and licensing of its proprietary software solutions to healthcare providers, hospitals, and medical research facilities. The company also offers maintenance and support services, which pro...
MeVis Medical Solutions Financial Statement Overview
Summary
Income Statement
72
Positive
Balance Sheet
90
Very Positive
Cash Flow
70
Positive
| Breakdown | TTM | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 16.64M | 16.06M | 16.97M | 17.34M | 18.76M | 16.21M |
| Gross Profit | 5.93M | 15.69M | 16.48M | 7.00M | 18.02M | 15.78M |
| EBITDA | 3.49M | 3.43M | 4.82M | 5.17M | 7.97M | 4.77M |
| Net Income | 4.30M | 3.17M | 4.56M | 4.92M | 7.79M | 4.55M |
Balance Sheet | ||||||
| Total Assets | 23.60M | 25.89M | 26.48M | 28.05M | 31.20M | 27.53M |
| Cash, Cash Equivalents and Short-Term Investments | 2.57M | 6.52M | 6.53M | 7.74M | 9.32M | 7.62M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 5.60M | 8.06M | 8.66M | 10.23M | 13.38M | 9.71M |
| Stockholders Equity | 18.01M | 17.83M | 17.83M | 17.83M | 17.83M | 17.83M |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 3.74M | 2.84M | 5.77M | 4.72M | 9.08M |
| Operating Cash Flow | 0.00 | 3.88M | 3.15M | 5.85M | 4.86M | 9.13M |
| Investing Cash Flow | 0.00 | 945.46K | 906.80K | 989.98K | 58.66K | 111.63K |
| Financing Cash Flow | 0.00 | -4.56M | -4.92M | -7.79M | -4.55M | -5.70M |
MeVis Medical Solutions Technical Analysis
Negative
24.60
Price Trends
23.71
Negative
23.87
Negative
23.99
Negative
Market Momentum
-0.31
Negative
38.29
Neutral
50.00
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:M3V, the sentiment is Negative. The current price of 24.6 is above the 20-day moving average (MA) of 22.94, above the 50-day MA of 23.71, and above the 200-day MA of 23.99, indicating a bearish trend. The MACD of -0.31 indicates Negative momentum. The RSI at 38.29 is Neutral, neither overbought nor oversold. The STOCH value of 50.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for DE:M3V.
MeVis Medical Solutions Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | €42.95M | ― | 13.44% | 3.86% | -5.36% | -30.58% | |
71 Outperform | €901.06M | 22.05 | 20.78% | 1.11% | 6.84% | 43.33% | |
65 Neutral | €1.36B | 37.27 | 9.79% | 3.46% | 4.23% | 32.89% | |
61 Neutral | €37.27B | 20.17 | 11.59% | 2.13% | -0.33% | 0.15% | |
60 Neutral | €1.43B | 49.73 | 4.19% | 0.20% | 1.16% | -43.53% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
49 Neutral | €203.73M | -30.34 | -0.10% | 2.71% | ― | ― |
* General Sector Average
DE:M3V
MeVis Medical Solutions
23.60
-1.26
-5.08%
DE:COP
CompuGroup Medical
27.15
5.54
25.66%
DE:DRW8
Draegerwerk AG & Co. KGaA
65.20
14.21
27.86%
DE:EUZ
Eckert & Ziegler Strahlen und Medizintechnik
14.40
-6.87
-32.29%
DE:SBS
STRATEC Biomedical
16.76
-8.51
-33.68%
DE:SHL
Siemens Healthineers AG
33.40
-14.66
-30.51%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.